OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Jahanzeb on the Benefit of Pertuzumab Plus Trastuzumab in HER2+ Breast Cancer

April 5th 2018

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the benefit of pertuzumab (Perjeta) plus trastuzumab (Herceptin) for patients with HER2-positive breast cancer.

Dr. Bellmunt on The Cancer Genome Atlas Project in Bladder Cancer

April 5th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.

Dr. Mesa Discusses Emerging Treatments for MPNs

April 5th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses emerging treatment for myeloproliferative neoplasms (MPNs).

Dr. Mahtani on TEXT and SOFT Trial Data in HR+ Breast Cancer

April 5th 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the updated data from the TEXT and SOFT clinical trials in premenopausal women with hormone-receptor positive (HR+) breast cancer.

Dr. Wei on the Use of Cabozantinib in Advanced Kidney Cancer

April 5th 2018

Xiao X. Wei, MD, MAS, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the side effect profile of cabozantinib (Cabometyx) in advanced kidney cancer.

Dr. van Besien on Autologous Stem Cell Transplantation in Hematologic Malignancies

April 4th 2018

Koen van Besien, MD, PhD, director, Stem Cell Transplant Program, professor of medicine, Weill Cornell Medical College, attending physician, NewYork-Presbyterian Hospital, discusses use of autologous stem cell transplantation in large cell lymphoma and multiple myeloma.

Dr. Goy on the Importance of MRD Status in Patients With MCL

April 4th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the importance of achieving minimal residual disease (MRD) negativity in mantle cell lymphoma (MCL).

Dr. Den Discusses Bone Metastases in Prostate Cancer

April 4th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone metastases in prostate cancer.

Dr. Sonpavde on Immunotherapy Plus Chemotherapy in Bladder Cancer

April 4th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy plus chemotherapy in bladder cancer.

Dr. Brentjens on Managing Patients After CAR T-Cell Therapy

April 4th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses managing patients after treatment with chimeric antigen receptor (CAR) T-cell therapy.

Dr. Sullivan Discusses the Current Treatment of Melanoma

April 4th 2018

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses the current treatment of patients with melanoma.

Dr. Domchek Discusses Areas of Investigation in Breast Cancer

April 4th 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses areas of investigation in breast cancer.

Dr. Verma Discusses Combinations With Biosimilars

April 4th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the possibility of combining biosimilars.

Dr. Helft Discusses Pancreatic and Carcinoid NETs

April 3rd 2018

Paul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses pancreatic and carcinoid neuroendocrine tumors.

Dr. Bouvet Discusses Risk Factors for Thyroid Cancer

April 3rd 2018

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses risk factors for thyroid cancer.

Dr. Winer Discusses Immunotherapy in Gynecologic Malignancies

April 3rd 2018

Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Dr. Bekaii-Saab Discusses the Next Steps With Regorafenib in CRC

April 3rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps following for regorafenib (Stivarga) in colorectal cancer (CRC).

Dr. Leslie Discusses CAR T-Cell Therapy in MCL

April 3rd 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

Dr. Lonial Discusses Novel Agents in Multiple Myeloma

April 3rd 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses novel agents for the treatment of patients with multiple myeloma.

Dr. Durand Discusses Treatment Options for Toxicities from Therapy in HER2+ Breast Cancer

April 2nd 2018

Jean-Bernard Durand, MD, professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses advice for community oncologists on managing patients that are experiencing symptoms from treatment for HER2-positive breast cancer.